PMID- 16099337
OWN - NLM
STAT- MEDLINE
DCOM- 20051013
LR  - 20151119
IS  - 0188-4409 (Print)
IS  - 0188-4409 (Linking)
VI  - 36
IP  - 5
DP  - 2005 Sep-Oct
TI  - Ozone therapy effects on biomarkers and lung function in asthma.
PG  - 549-54
AB  - BACKGROUND: The relationship and behavior of serum immunoglobulin E (IgE) level, 
      peripheral blood mononuclear cell (PBMC) human leukocyte antigen DR (HLA-DR) 
      expression and erythrocyte glutathione antioxidant pathway in asthma patients 
      treated with systemic ozone therapy have not been studied before. METHODS: Asthma 
      patients were treated about 1 year with three cycles (5 or 6 months each) with 
      three different ozone therapy protocols. Ozone major autohemotherapy (MAHT) was 
      applied at doses of 4 and 8 mg, 15 sessions each cycle; and ozone rectal 
      insufflations (RI) at a dose of 10 mg, 20 sessions each cycle. Serum IgE, HLA-DR 
      expression in PBMC and biomarkers for antioxidant pathway were measured before 
      and at the end of each cycle. Lung function and symptoms test were recorded at 
      the beginning and after the third cycle. RESULTS: IgE and HLA-DR decreased with 
      the three types of treatments, while increments in reduced glutathione, 
      glutathione peroxidase, glutation reductase and glutathione S-transferase were 
      achieved with all treatments. Lung function and symptoms test were markedly 
      improved. However, in all parameters the best response was obtained in the order: 
      MAHT at 8 mg better than MAHT at 4 mg better than RI at 10 mg. Before ozone 
      treatment, glutathione antioxidant parameters were under the normal reference 
      values, suggesting the occurrence of oxidative stress associated with atopic 
      asthma. CONCLUSIONS: This study demonstrates the effectiveness of ozone therapy 
      in reducing IgE and inflammatory mediators along with the induction of 
      antioxidant elements. The study raises the role of systemic ozone therapy in 
      atopic asthma by means of its immunomodulatory and oxidative stress regulation 
      properties.
FAU - Hernandez Rosales, Frank A
AU  - Hernandez Rosales FA
AD  - Departmento de Biomedicina, Centro de Investigaciones del Ozono del Centro 
      Nacional de Investigaciones Cientificas, Ciudad de la Habana, Cuba. 
      frank.hernandez@cnic.edu.cu
FAU - Calunga Fernandez, Jose L
AU  - Calunga Fernandez JL
FAU - Turrent Figueras, Jose
AU  - Turrent Figueras J
FAU - Menendez Cepero, Silvia
AU  - Menendez Cepero S
FAU - Montenegro Perdomo, Adonis
AU  - Montenegro Perdomo A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Oxidants, Photochemical)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 66H7ZZK23N (Ozone)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.8.1.7 (Glutathione Reductase)
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antioxidants/metabolism
MH  - Asthma/immunology/*therapy
MH  - *Biomarkers
MH  - Bronchial Hyperreactivity
MH  - Female
MH  - Glutathione/metabolism
MH  - Glutathione Peroxidase/metabolism
MH  - Glutathione Reductase/metabolism
MH  - Glutathione Transferase/metabolism
MH  - HLA-DR Antigens/blood/immunology
MH  - Humans
MH  - Immunoglobulin E/blood/immunology
MH  - Lung/*physiology
MH  - Male
MH  - Middle Aged
MH  - Oxidants, Photochemical/*therapeutic use
MH  - Ozone/*therapeutic use
EDAT- 2005/08/16 09:00
MHDA- 2005/10/14 09:00
CRDT- 2005/08/16 09:00
PHST- 2005/02/18 00:00 [received]
PHST- 2005/04/22 00:00 [accepted]
PHST- 2005/08/16 09:00 [pubmed]
PHST- 2005/10/14 09:00 [medline]
PHST- 2005/08/16 09:00 [entrez]
AID - S0188-4409(05)00246-8 [pii]
AID - 10.1016/j.arcmed.2005.04.021 [doi]
PST - ppublish
SO  - Arch Med Res. 2005 Sep-Oct;36(5):549-54. doi: 10.1016/j.arcmed.2005.04.021.